Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

BACKGROUND: In patients with advanced non-squamous non-small cell lung cancer (NSCLC), a pemetrexed/cisplatin (PP) regimen is considered as one of the preferred first-line treatments. However, only about half of the treated patients respond, and there is no clinically useful marker that can predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hong, Fang, Xue-Feng, Yuan, Ying, Yang, Jiao, Zheng, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649948/
https://www.ncbi.nlm.nih.gov/pubmed/29147418
http://dx.doi.org/10.14740/wjon901w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649948/
https://www.ncbi.nlm.nih.gov/pubmed/29147418
http://dx.doi.org/10.14740/wjon901w

Ejemplares similares